Valuation

The industry is poised for strong growth, backed by rising stainless steel adaptability across sectors and government initiatives for mega infrastructure projects. The thriving manufacturing industry, sustainable construction, automotive sector, consumer durables, and growing new-age sector are expected to steadily propel India’s stainless steel consumption to 7.3mt by FY31 and 12.5-20mt by 2047. JSL has evolved from being solely a flat SS producer to a diversified long SS player, expanding into rebar, wire rods, and decorative SS, unlocking significant infrastructure opportunities. Additionally, its focus on value-added CR SS strengthens its position in both domestic and export markets. Considering these tailwinds, JSL’s revenue CAGR is projected to be ~14% over FY25-27, outperforming other carbon steel players in the industry. With steady margins of INR20,500-22,000/t, EBITDA is expected to reach ~17% CAGR over FY25-27. A healthy CFO and steady capex outflow will ensure JSL’s B/S remains resilient.

Scenarios analysis

Bull Case  Robust economic growth, coupled with supportive government initiatives like the PLI scheme and Make in India, is set to boost demand across sectors like infrastructure, railways, automotive, new-age industries, and the defense sector, fueling stainless steel demand in India. Additionally, the tariff barriers on Chinese imports will safeguard domestic players, creating a level playing field.  Revenue is projected to post ~21% CAGR, reaching ~INR573b over FY25-27. This growth will be driven by strong volume expansion from the ramp-up of new capacities and healthy NSR, supported by a higher VAP share.  Strategic investments in renewable energy and backward integration for cost control are expected to drive margin accretion. With EBITDA improving to INR23,500/t (vs. FY25 reported EBITDA), it is expected to result in a 26% CAGR, reaching INR74b over FY25-27.

Bear Case  A slowdown in domestic demand could hinder stainless steel volume growth. Furthermore, cheap stainless steel imports from China may erode the pricing power of domestic manufacturers. This could lead to sluggish volume CAGR of 8%, with flat NSR over FY25-FY27. As a result, revenue is expected to post an 8% CAGR, where volume gains may offset the any negative impact led by weaker NSR.  Geopolitical tensions and logistical challenges could disrupt raw material availability, causing price volatility and supply chain disruptions. This may impact business operations, resulting in operating margin moderation. Hereby company could see modest EBITDA of INR20,000/t (vs. INR19,600/t in FY25) could result in ~9% CAGR for EBITDA, reaching INR55b over FY25-27.

Strengths

 JSL is the largest stainless steel manufacturer in India with a dominant market share.  It offers a wide range of stainless steel grades (200, 300, 400 series), catering to various sectors like automotive, railways, construction, new-age, and defense.  JSL is strengthening raw material security through backward integration by investing in an NPI plant in Indonesia.  The company demonstrates a strong commitment to renewable energy (wind, solar), circular economy (slag recycling, metal recovery), and biofuel integration.  Recent strategic acquisitions and capacity expansions provide long-term growth headroom.

Weaknesses

 JSL has a heavy dependency on nickel, stainless steel scrap, and ferroalloys, which are subject to price fluctuations and can impact profitability.  Capital-intensive expansion may strain short-term cash flows.  Competitive pricing pressures from imported stainless steel limit the company's ability to pass on costs further in the supply chain.  Compliance with environmental norms, carbon taxation (CBAM), and safety regulations requires continuous investment and adaptation.  The industry is highly exposed to cyclicality and dependent on broader economic trends, leading to a volatile profitability outlook.

Opportunities

 The growing adaptability of stainless steel in railways (Vande Bharat), metro projects, infrastructure, and defense leads to significant growth potential.  Policies like Make in India, the PLI scheme, and potential anti-dumping duties on Chinese imports could strengthen domestic business.  Expansion into value-added & specialty products will allow JSL to focus on high-margin products like defense-grade and lightweight automotive alloys.  The increasing global demand for sustainable and high-quality stainless steel offers opportunities for expanding exports.  JSL has implemented various green initiatives, such as floating solar plants, biofuel integration, and slag recycling position.

Threats

 Cheap Imports from China and Indonesia, especially in the 200 series, could disrupt domestic pricing and margins.  Fluctuations in nickel, chromium, and scrap steel prices may impact cost structures, leading to margin pressure.  Geopolitical and supply chain disruptions may affect raw material procurement and create logistics challenges.  A demand slowdown could result from sluggish growth in the infrastructure, automotive, or real estate sectors.  The implementation of EU CBAM and other environmental levies could increase export costs

🚨 Semiconductor investments approved by India.

1. Micron Technology - Rs 22,516 crore - Sanand, Gujarat.

2. Tata Electronics & Powerchip - Rs 91,000 crore - Dholera, Gujarat.

3. Tata Electronics - Rs 27,000 crore - Morigaon, Assam.

4. CG Power + Renesas + Stars Microelectronics - Rs 7,600 crore - Sanand, Gujarat.

5. Kaynes Semicon - Rs 3,300 crore - Sanand, Gujarat.

6. HCL + Foxconn JV - Rs 3,706 crore - Jewar, Uttar Pradesh.

As of now, The union cabinet has approved six semiconductor investments.

Good morning

Aster DM Healthcare Limited Company Details Report

Aster DM Healthcare Limited is one of the largest integrated private healthcare service providers operating in India with a strong presence across primary, secondary, tertiary and quaternary healthcare. At present, ~70% of the business comes from tier-II and tierIII cities. As on 31st December 2024, it has presence in Southern & Western region, in the states of Karnataka (Hospital: 4, Beds: 1,192); Maharashtra (Hospital: 1, Beds: 254); Andhra Pradesh (Hospital: 6, Beds: 889); Telangana (Hospital:1, Beds: 158) and Kerala Hospital (Hospital: 6, Beds: 2,635). As on 31st December 2024, it has 19 hospitals with a total capacity of 5,128 beds, 13 clinics, 203 pharmacies (operated by Alfaone Retail Pharmacies Pvt Ltd under brand license from Aster) and 254 labs & patient experience centers across 5 states in India. Of the total capacity, ~3,766 beds are currently operational. The company has successfully concluded the segregation of its India and GCC (Gulf Cooperation Council) business on 3rd April 2024 for an equity value of $1bn (₹8,215 cr). In FY24, GCC business contributed 74% to the total revenue.

Business Revenue

Specialty business revenue

Hospitals business

#SALES #GROWTH 5 Year CAGR 23.0%

In FY24, revenue grew by ~24% YoY to ₹3,699 cr, led by bed capacity increase of ~550 beds and a 10% rise in ARPOB. Regionally, Kerala, Karnataka and AP clusters grew by ~19%, ~35% and ~20%, respectively. In 9M FY25, sales grew by ~15% YoY to ₹3,138 cr, driven by ~4% increase in occupied beds and ~12% rise in ARPOB levels. Revenue from the new business (labs & pharmacies) declined by ~3% YoY to ₹208 cr. The geographical revenue mix during 9M FY25 was - Kerala 53%, Karnataka & Maharashtra 35% and Andhra & Telangana 12%. On the revenue front, Kerela, Karnataka & Maharashtra and Andhra & Telangana sales was up by ~8%, ~33% and ~16%, respectively on a YoY basis, primarily on account of rising ARPOB levels, IP (in-patient) and OP (outpatient) volumes. However, Kerala cluster observed lower growth due to factors like changing flu season during the period, impacting footfalls.

#EBITDA #GROWTH

In FY24, EBITDA increased by ~29% YoY to ₹578 cr. The performance was aided by improved operating performance across matured hospitals. In 9M FY25, EBITDA grew by ~37% YoY to ₹572 cr. This was supported by growth in operating profit. Cluster-wise, operating EBITDA stood at: Kerala ₹382 cr (v/s ₹317 cr in 9M FY24), Karnataka & Maharashtra ₹244 cr (v/s ₹154 cr in 9M FY24) and Andhra & Telangana ₹47 cr (v/s ₹33 cr in 9M FY24). Additionally, manpower costs and overheads also contributed through operating leverage to this growth. The capacity expansion, ARPOB growth, increasing international revenue as well as focus on advanced quaternary and tertiary healthcare services is likely to aid in further improvement across operating performance

#PAT #GROWTH

In FY24, PAT stood at ₹216 cr, up by ~26% YoY. The growth was aided by an improved topline and operating profit growth, partially offset by increase in depreciation and interest costs. Excluding the share of loss of equity accounted investees, the same grew by ~28% to ₹205 cr. In 9M FY25, PAT was ₹251 cr, a growth of ~54% YoY, showcasing strong operational performance and increased other income, attributable towards investing proceeds from the GCC (Gulf Corporation Council) business segregation. However, excluding a one-off merger transaction cost of ~₹24 cr, the same was up by ~69% YoY to ₹275 cr. Keeping in view the company’s expansion plans, it is likely that the depreciation expense will continue to remain on the higher side.

#EBITDA #MARGIN

In FY24, EBITDA margin expanded by 63 bps YoY to 15.6%, supported by cost efficiencies, operating leverage and labs breakeven during the period. In 9M FY25, EBITDA margin expanded by ~288 bps YoY to 18.2%, on account of strategic cost optimization strategies, reduction in ALOS and enhanced EBITDA performance in the lab business. The core hospital business posted an operating EBITDA margin of ~22%. While the margins for mature hospitals expanded by ~300 bps YoY to 25%. Cluster-wise, operating EBITDA margin for Kerala was 23.7% (v/s 21.3% in 9M FY24), Karnataka & Maharashtra 23.2% (v/s 19.4% in 9M FY24) and Andhra & Telangana 13.2% cr (v/s 10.8% in 9M FY24). In India, its is focusing on large-format hospitals in tier-1 cities which are expected to deliver higher margins. This may be partially offset by losses incurred at the newly commissioned hospitals.

#PAT #MARGIN

In FY24, PAT margin was 5.4%, an expansion of 14 bps YoY. In 9M FY25, PAT margin was 8%, an expansion of 202 bps YoY. However, excluding a one-off merger transaction cost, the same witnessed an expansion of ~278 bps YoY to 8.8%.

#ROCE

In FY24, ROCE for the company stood at 5.76%. The increase in the ratio was supported by an improvement in PBIT. ROCE at a consolidated level stood at ~19% in 9M FY25. Whereas ROCE for the hospital and clinics segment was ~26% in 9M FY25 v/s ~21% in 9M FY24; mature hospitals witnessed an increase in the same to ~36% during the period.

#ROE

In FY24, ROE for the company witnessed an increase to 4.97%, aided by improved profit growth. The company has a focused presence in Southern and Western India, delivering quality healthcare services which in turn drives patient volumes. Strong patient volumes post-pandemic and cost efficiency drove the overall profit and improved the ROE. The company is foraying across new facilities which would help to widen its patient base. This will help in improving the profitability and maintaining strong return ratios of the company going ahead.